tbuckley/cabot-search huggingface dataset:
Stent misdeployment and factors associated with failure in EUS-guided choledochoduodenostomy: an analysis of the combined datasets from the ELEMENT and DRA-MBO trials
Authors: Yen-I Chen, Clara Long, Anand V. Sahai, Bertrand Napoleon, Gianfranco Donatelli, Rastislav Kunda, Myriam Martel, Shannon M. Chan, Paolo G. Arcidiacono, Eric Lam, Pradermchai Kongkam, Nauzer Forbes, Alberto Larghi, Jeffrey D. Mosko, Schalk Van der Merwe, Seng Ian Gan, Jeremie Jacques, Sana Kenshil, Thawee Ratanachu-Ek, Corey Miller, Payal Saxena, Etienne Desilets, Gurpal Sandha, Yousef Alrifae, Anthony Y. B. Teoh
Journal: Endoscopy (2024)

Stent misdeployment (SMD) is a feared and poorly characterized technical challenge of endoscopic ultrasound (EUS)-guided choledochoduodenostomy (CDS) using lumen-apposing stents. We aimed to ascertain the rate of stent misdeployment in EUS-CDS for malignant distal biliary obstruction (MDBO) and describe its outcomes while identifying variables associated with its occurrence.
The adaptation of a single institution diabetes care platform into a nationally available turnkey solution
Authors: Gloria Y. K. Kim, Rea Rostosky, Franziska K. Bishop, Kelly Watson, Priya Prahalad, Aishwari Vaidya, Sharon Lee, Alexander Diana, Clint Beacock, Brian Chu, Ginny Yadav, Kaylin Rochford, Carissa Carter, Johannes O. Ferstad, Erica Pang, Jamie Kurtzig, Brandon Arbiter, Howard Look, Ramesh Johari, David M. Maahs, David Scheinker
Journal: npj Digital Medicine (2024)

Digital decision support and remote patient monitoring may improve outcomes and efficiency, but rarely scale beyond a single institution. Over the last 5 years, the platform Timely Interventions for Diabetes Excellence (TIDE) has been associated with reduced care provider screen time and improved, equitable type 1 diabetes care and outcomes for 268 patients in a heterogeneous population as part of the Teamwork, Targets, Technology, and Tight Control (4T) Study (NCT03968055, NCT04336969). Previous efforts to deploy TIDE at other institutions continue to face delays. In partnership with the diabetes technology non-profit, Tidepool, we developed Tidepool-TIDE, a clinic-agnostic, turnkey solution available to any clinic in the United States. We present how we overcame common technical and operational barriers specific to scaling digital health technology from one site to many. The concepts described are broadly applicable for institutions interested in facilitating broader adoption of digital technology for population-level management of chronic health conditions.
SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study
Authors: Henrik Svanström, George Frederick Mkoma, Anders Hviid, Björn Pasternak
Journal: BMJ (2024)

Abstract Objective To investigate the association between sodium-glucose cotransporter-2 (SGLT-2) inhibitor use and risk of all cause mortality among patients with heart failure with reduced ejection fraction. Design Linked database study. Setting National registers in Denmark, July 2020 to June 2023. Participants Patients with heart failure, aged ≥45 years, with left ventricular ejection fraction ≤40%. Main outcome measures The primary outcome was all cause mortality comparing initiation and continued treatment with SGLT-2 inhibitors versus continued treatment with other standard-of-care heart failure drugs and non-use of SGLT-2 inhibitors; secondary outcomes were the composite of cardiovascular mortality or admission to hospital with heart failure and its individual components. Hazard ratios were estimated using Cox regression adjusted using inverse probability of treatment weighting based on propensity scores. Results The study included 6776 patients who started SGLT-2 inhibitors (79% dapagliflozin; 21% empagliflozin) and 14 686 patients who remained on other standard-of-care heart failure drugs and did not use SGLT-2 inhibitors. Most SGLT-2 inhibitor users were male (70%), the mean age was 71.2 (standard deviation 10.6) years, and 20% had type 2 diabetes. During follow-up, 374 deaths occurred among SGLT-2 inhibitor users (incidence rate 5.8 per 100 person years) and 1602 among non-users (8.5 per 100 person years). The weighted hazard ratio for all cause mortality was 0.75 (95% confidence interval 0.66 to 0.85); the weighted incidence rate difference was −1.6 (95% confidence interval −2.5 to −0.8) per 100 person years. Secondary outcomes showed a weighted hazard ratio of 0.94 (0.85 to 1.04) for cardiovascular mortality or hospital admission with heart failure, 0.77 (0.64 to 0.92) for cardiovascular mortality, and 1.03 (0.92 to 1.15) for hospital admission with heart failure. The weighted hazard ratios for all cause mortality were consistent in patients with and without diabetes (0.73 (0.58 to 0.91) and 0.73 (0.63 to 0.85); P=0.99). Conclusions In this large database study among patients with heart failure with reduced ejection fraction, SGLT-2 inhibitor use was associated with a 25% lower risk of all cause mortality, supporting their effectiveness in routine clinical practice.
Proton pump inhibitor attenutes acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis of solid tumors
Authors: Xuejia Zhai, Ling Mao, Qingmei Kang, Jie Liu, Yu Zhou, Jun Wang, Xianyan Yang, Di Wang, Junhan Wang, Yao Li, Jiangjie Duan, Tao Zhang, Shuang Lin, Tingting Zhao, Jianjun Li, Min Wu, Shicang Yu
Journal: Molecular Therapy (2024)
Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin αvβ3-positive tumors: a first-in-human study
Authors: Huimin Sui, Feng Guo, Hongfei Liu, Rongxi Wang, Linlin Li, Jiarou Wang, Chenhao Jia, Jialin Xiang, Yingkui Liang, Xiaohong Chen, Zhaohui Zhu, Fan Wang
Journal: Acta Pharmaceutica Sinica B (2024)

Integrin α v β 3 is overexpressed in various tumor cells and angiogenesis. To date, no drug has been proven to target it for therapy. A first-in-human study was designed to investigate the safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2, a novel integrin α v β 3-targeting radionuclide drug with an albumin-binding motif to optimize the pharmacokinetics. Ten patients (3 men, 7 women; aged 45 ± 16 years) with integrin α v β 3-avid tumors were recruited to accept 177Lu-AB-3PRGD2 injection in a dosage of 1.57 ± 0.08 GBq (42.32 ± 2.11 mCi), followed by serial scans to obtain its dynamic distribution in the body. Safety tests were performed before and every 2 weeks after the treatment for 6-8 weeks. No adverse event over grade 3 was observed. 177Lu-AB-3PRGD2 was excreted mainly through the urinary system, with intense radioactivity in the kidneys and bladder. Moderate distribution was found in the liver, spleen, and intestines. The estimated blood half-life was 2.85 ± 2.17 h. The whole-body effective dose was 0.251 ± 0.047 mSv/MBq. The absorbed doses were 0.157 ± 0.032 mGy/MBq in red bone marrow and 0.684 ± 0.132 mGy/MBq in kidneys. This first-in-human study of 177Lu-AB-3PRGD2 treatment indicates its promising potential for targeted radionuclide therapy of integrin α v β 3-avid tumors. It merits further studies in more patients with escalating doses and multiple treatment courses.
Influence of comorbidities on health-related quality of life in alcohol-related liver disease: a population-based survey
Authors: Karen Dombestein Elde, Peter Jepsen, Natasja Von Wowern, Matilde Winther-Jensen, Marie Holm Eliasen, Anne Illemann Christensen, Lone Galmstrup Madsen, Gro Askgaard
Journal: Clinical Gastroenterology and Hepatology (2024)
Epithelial–mesenchymal transition to Mitigate Age-Related Progression in Lung Cancer
Authors: Riya Thapa, Saurabh Gupta, Gaurav Gupta, Asif Ahmad Bhat, None Smriti, Madhav Singla, Haider Ali, Sachin Kumar Singh, Kamal Dua, Manoj Kumar Kashyap
Journal: Ageing Research Reviews (2024)
Therapeutic Efficacy of Platelet-Rich Plasma Combining with Microneedling and Topical Minoxidil in Refractory Severe Androgenic Alopecia
Authors: Yanhua Li, Chenlei Dai, Yizhou Wang, Guangyu Lu, Jun Zhang, Yuqian Li, Guanghui Shao, Xiaoqin Jia, Xufeng Du
Journal: Journal of the American Academy of Dermatology (2024)
The Effect of BCG Vaccination in the Elderly on Infectious and Non-Infectious Immune-Mediated Diseases
Authors: Elisabeth A Dulfer, Konstantin Föhse, Esther J M Taks, Simone J C F M Moorlag, Eva L Koekenbier, Josephine S van de Maat, Jaap Ten Oever, Jacobien J Hoogerwerf, Cornelis H van Werkhoven, Marc J M Bonten, Astrid van Hylckama Vlieg, Frits R Rosendaal, Mihai G Netea
Journal: Journal of Infection (2024)
Biologics-based technologies for highly efficient and targeted RNA delivery
Authors: Anastasiya Kostyusheva, Sergey Brezgin, Natalia Ponomareva, Anastasiia Frolova, Alexander Lunin, Ekaterina Bayurova, Andrey Tikhonov, Olga Slatinskaya, Polina Demina, Artyom Kachanov, Gulalek Babayeva, Irina Khan, Dmitry Khochenkov, Yulia Khochenkova, Darina Sokolova, Denis Silachev, Georgy Maksimov, Evgeny Khaydukov, Vadim S. Pokrovsky, Andrey A. Zamyatnin, Alessandro Parodi, Ilya Gordeychuk, Vladimir Chulanov, Dmitry Kostyushev
Journal: Molecular Therapy (2024)
AAVrh.10 Delivery of Novel APOE2-Christchurch Variant Suppresses Amyloid and Tau Pathology in Alzheimer’s Disease Mice
Authors: Caner Günaydin, Dolan Sondhi, Stephen M Kaminsky, Hailey C Lephart, Philip L Leopold, Neil R Hackett, Richie Khanna, Ronald G Crystal
Journal: Molecular Therapy (2024)
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial
Authors: Pratima Chowdary, Pantep Angchaisuksiri, Shashikant Apte, Jan Astermark, Gary Benson, Anthony K C Chan, Victor Jiménez Yuste, Tadashi Matsushita, Amalie Rhode Høgh Nielsen, Jameela Sathar, Christopher Sutton, Sonata Šaulytė Trakymienė, Huyen Tran, Laura Villarreal Martinez, Allison P Wheeler, Jerzy Windyga, Guy Young, Jay Jay Thaung Zaw, Hermann Eichler
Journal: The Lancet Haematology (2024)
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study
Authors: Prasad S Kulkarni, Anand Kawade, Sunil Kohli, Renuka Munshi, Chetna Maliye, Nithya J Gogtay, Ravish H S, Kiranjit Singh, K Vengadakrishnan, Sandeep Kumar Panigrahi, Jyotiranjan Sahoo, Ashish Bavdekar, B S Garg, Abhishek Raut, Jeffrey P Raj, Unnati Saxena, Vijaya L Chaudhari, Rakesh Patil, Epari Venkatarao, Nitu Kumari, Jithin Surendran, Varsha Parulekar, Luc Gagnon, Tania Gensale, Abhijeet Dharmadhikari, Sunil Gairola, Sameer Kale, Sambhaji S Pisal, Rajeev M Dhere, Asha Mallya, Cyrus S Poonawalla, Dhananjay Kapse
Journal: The Lancet Infectious Diseases (2024)
SENIOR-RITA — Is It All about Angiography?
Authors: Simone Biscaglia
Journal: New England Journal of Medicine (2024)

In the British Heart Foundation SENIOR-RITA (Older Patients with Non–ST-Segment Elevation Myocardial Infarction Randomized Interventional Treatment) trial, patients 75 years of age or older with non–ST-segment elevation myocardial infarction (NSTEMI) were randomly assigned to receive treatment that was based on a conservative-treatment strategy or an invasive-treatment strategy of coronary-artery angiography (and percutaneous coronary intervention [PCI] or coronary-artery bypass grafting, if indicated).1 There was no difference between the two groups in terms of a composite of cardiovascular death or nonfatal myocardial infarction (the primary end point) or in death from any cause. The patients in the invasive-treatment group had fewer nonfatal . . .
Randomized Trial of Very Early Medication Abortion
Authors: Karin Brandell, Tagrid Jar-Allah, John Reynolds-Wright, Helena Kopp Kallner, Helena Hognert, Frida Gyllenberg, Janina Kaislasuo, Anand Tamang, Heera Tuladhar, Clare Boerma, Karen Schimanski, Gillian Gibson, Mette Løkeland, Pia Teleman, Marie Bixo, Mette Mandrup Kjaer, Ervin Kallfa, Johan Bring, Oskari Heikinheimo, Sharon Cameron, Kristina Gemzell-Danielsson
Journal: New England Journal of Medicine (2024)

BackgroundMedication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a pregnancy can be visualized with ultrasonography.MethodsWe conducted a multicenter, noninferiority, randomized, controlled trial involving women requesting medication abortion at up to 42 days of gestation with an unconfirmed intrauterine pregnancy on ultrasound examination (visualized as an empty cavity or a sac-like structure without a yolk sac or embryonic pole). Participants were randomly assigned to either immediate start of abortion (early-start group) or standard-care treatment delayed until intrauterine pregnancy was confirmed (standard group). The primary outcome was complete abortion. The noninferiority margin was set at 3.0 percentage points for the absolute between-group difference.Download a PDF of the Plain Language Summary.ResultsIn total, 1504 women were included at 26 sites in nine countries and were randomly assigned to the early-start group (754 participants) or the standard group (750 participants). In an intention-to-treat analysis, a complete abortion occurred in 676 of 710 participants (95.2%) in the early-start group and in 656 of 688 (95.3%) in the standard group; the absolute between-group difference was −0.1 percentage points (95% confidence interval, −2.4 to 2.1). Ectopic pregnancies occurred in 10 of 741 participants (1.3%) in the early-start group and in 6 of 724 (0.8%) in the standard group, with one rupture before diagnosis (early-start group). Serious adverse events occurred in 12 of 737 participants (1.6%) in the early-start group and in 5 of 718 (0.7%) in the standard group (P=0.10); the majority were uncomplicated hospitalizations for treatment of ectopic pregnancy or incomplete abortion.ConclusionsMedication abortion before confirmed intrauterine pregnancy was noninferior to standard, delayed treatment with respect to complete abortion. (Funded by the Swedish Research Council and others; VEMA EudraCT number, 2018-003675-35; ClinicalTrials.gov number, NCT03989869.) Quick Take A Trial of Very Early Medication Abortion 1m 48s
Simple Strategies to Reduce Cardiac Strain in Older Adults in Extreme Heat
Authors: Georgia K Chaseling, Nicole T Vargas, Lily Hospers, Hadiatou Barry, Amy Harwood, Connor Graham, Audrey-Ann Bartlett, Amélie Debray, Grant Lynch, Anthony Capon, Craig G Crandall, Maria Fiatarone Singh, Yorgi Mavros, Peng Bi, Anil Nigam, Malorie Chabot-Blanchet, Daniel Gagnon, Ollie Jay
Journal: New England Journal of Medicine (2024)

In this crossover trial in older adults with or without coronary artery disease, cardiac strain was reduced with fan use, skin wetting, or both in hot and humid conditions but worsened with fan use in very hot and dry conditions.
Reply to: Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide-Based Mismatched Unrelated Donor Transplantation
Authors: Brian C. Shaffer, Mahasweta Gooptu, Todd DeFor, Stephen R. Spellman, Heather E. Stefanski, Bronwen E. Shaw, Jeffery J. Auletta, Steven M. Devine, Antonio M. Jimenez, Monzr M. Al Malki
Journal: Journal of Clinical Oncology (2024)
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
Authors: Georgina V. Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D. Lao, Iván Márquez-Rodas, John Wagstaff, Céleste Lebbé, Jacopo Pigozzo, Caroline Robert, Paolo A. Ascierto, Victoria Atkinson, Michael A. Postow, Michael B. Atkins, Mario Sznol, Margaret K. Callahan, Suzanne L. Topalian, Jeffrey A. Sosman, Srividya Kotapati, Pratik K. Thakkar, Corey Ritchings, Melanie Pe Benito, Sandra Re, Samira Soleymani, F. Stephen Hodi
Journal: Journal of Clinical Oncology (2024)

Nivolumab (NIVO) + ipilimumab (IPI) combination and NIVO monotherapy have demonstrated durable clinical benefit in patients with unresectable/metastatic melanoma. This analysis describes long-term overall survival (OS) with the combination or monotherapy pooled across all major company-sponsored trials, as well as clinical factors associated with survival, in patients with immune checkpoint inhibitor (ICI) treatment-naïve unresectable/metastatic melanoma. Data were pooled from six CheckMate studies in ICI treatment-naïve patients receiving NIVO + IPI (NIVO 1 mg/kg + IPI 3 mg/kg or NIVO 3 mg/kg + IPI 1 mg/kg) or NIVO monotherapy (3 mg/kg). OS was assessed for each treatment, as well as in select subgroups. Cox proportional multivariate analysis (MVA) and classification and regression tree (CART) analyses were performed within treatment arms. Median follow-up for OS was 45.0 months for patients treated with NIVO + IPI (n = 839) and 35.8 months for patients treated with NIVO (n = 536). OS was longer with NIVO + IPI versus NIVO monotherapy (hazard ratio, 0.78 [95% CI, 0.67 to 0.91]), with 6-year OS rates of 52% versus 41%, respectively. Consistent benefit was observed in BRAF-mutant and BRAF-wild-type patients and those with normal and elevated lactate dehydrogenase (LDH). Numerical difference in OS was also observed across PD-L1 expression levels, although more pronounced with no/low PD-L1 expression. Clinical factors associated with decreased survival in both the MVA and CART analyses were LDH > upper limit of normal with either treatment, age ≥65 years with NIVO + IPI, and the presence of liver metastases with NIVO monotherapy. In this large, pooled nonrandomized retrospective analysis, we observed that NIVO + IPI provides longer OS than NIVO in patients with ICI treatment-naïve advanced melanoma and identifies clinical factors that appear to be associated with survival for each treatment, which may assist with treatment decision making.
Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project
Authors: Maria Teresa Voso, Luca Guarnera, Sören Lehmann, Konstanze Döhner, Hartmut Döhner, Uwe Platzbecker, Nigel H. Russell, Richard James Dillon, Ian Thomas, Gert J Ossenkoppele, Torsten Haferlach, Marco Vignetti, Edoardo La Sala, Alfonso Piciocchi, Paola Fazi, Ángela Villaverde Ramiro, Laura Tur Giménez, Carmelo Gurnari, Lars Bullinger, Jesus M. Hernandez
Journal: Blood (2024)
Glioblastoma functional heterogeneity and enrichment of cancer stem cells with tumor recurrence
Authors: Xuanhua P Xie, Mungunsarnai Ganbold, Jing Li, Michelle Lien, Mollie E Chipman, Tao Wang, Chenura D Jayewickreme, Alicia M Pedraza, Tejus Bale, Viviane Tabar, Cameron Brennan, Daochun Sun, Roshan Sharma, Luis F Parada
Journal: Neuron (2024)
Cardiovascular Risk Factors and Genetic Risk in Transthyretin V142I Carriers
Authors: Naman S Shetty, Mokshad Gaonkar, Akhil Pampana, Nirav Patel, Alanna C Morrison, Alexander P Reiner, April P Carson, Bing Yu, Bruce M Psaty, Charles Kooperberg, Diane Fatkin, Eric Boerwinkle, Jerome I Rotter, Kent D Taylor, Lifang Hou, Marguerite R Irvin, Michael E Hall, Mathew Maurer, Myriam Fornage, Nicole D Armstrong, Nicole Bart, Parag Goyal, Stephen S Rich, Ramachandran S Vasan, Peng Li, Garima Arora, Pankaj Arora
Journal: JACC Heart Failure (2024)
Hospitalized Advanced Heart Failure With Preserved vs Reduced Left Ventricular Ejection Fraction
Authors: Vasiliki Bistola, Dimitrios Farmakis, Jasper Tromp, Wan Ting Tay, Wouter Ouwerkerk, Christiane E Angermann, John G F Cleland, Ulf Dahlström, Kenneth Dickstein, Georg Ertl, Mahmoud Hassanein, Sotiria Liori, Petros Nikolopoulos, Sergio V Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Sean P Collins, Carolyn S P Lam, Gerasimos Filippatos
Journal: JACC Heart Failure (2024)
The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic Cardiomyopathy
Authors: Monica Ahluwalia, Jiankang Liu, Iacopo Olivotto, Victoria Parikh, Euan A Ashley, Michelle Michels, Jodie Ingles, Rachel Lampert, John C Stendahl, Steven D Colan, Dominic Abrams, Alexandre C Pereira, Joseph W Rossano, Thomas D Ryan, Anjali T Owens, James S Ware, Sara Saberi, Adam S Helms, Sharlene Day, Brian Claggett, Carolyn Y Ho, Neal K Lakdawala
Journal: JACC Heart Failure (2024)
A Survey of Few-Shot Learning for Biomedical Time Series
Authors: Chenqi Li, Timothy Denison, Tingting Zhu
Journal: IEEE Reviews in Biomedical Engineering (2024)

Advancements in wearable sensor technologies and the digitization of medical records have contributed to the unprecedented ubiquity of biomedical time series data. Data-driven models have tremendous potential to assist clinical diagnosis and improve patient care by improving long-term monitoring capabilities, facilitating early disease detection and intervention, as well as promoting personalized healthcare delivery. However, accessing extensively labeled datasets to train data-hungry deep learning models encounters many barriers, such as long-tail distribution of rare diseases, cost of annotation, privacy and security concerns, data-sharing regulations, and ethical considerations. An emerging approach to overcome the scarcity of labeled data is to augment AI methods with human-like capabilities to leverage past experiences to learn new tasks with limited examples, called few-shot learning. This survey provides a comprehensive review and comparison of few-shot learning methods for biomedical time series applications. The clinical benefits and limitations of such methods are discussed in relation to traditional data-driven approaches. This paper aims to provide insights into the current landscape of few-shot learning for biomedical time series and its implications for future research and applications.
The Physiome Project and Digital Twins
Authors: P. Hunter, B. de Bono, D. Brooks, R. Christie, J. Hussan, M. Lin, D. Nickerson
Journal: IEEE Reviews in Biomedical Engineering (2024)

Interest in the concept of a virtual human model that can encompass human physiology and anatomy on a biophysical (mechanistic) basis, and can assist with the clinical diagnosis and treatment of disease, appears to be growing rapidly around the globe. When such models are personalised and coupled with continual diagnostic measurements, they are called 'digital twins'. We argue here that the most useful form of virtual human model will be one that is constrained by the laws of physics, contains a comprehensive knowledge graph of all human physiology and anatomy, is multiscale in the sense of linking systems physiology down to protein function, and can to some extent be personalized and linked directly with clinical records. We discuss current progress from the IUPS Physiome Project and the requirements for a framework to achieve such a model.
A Prospective Analysis of Per- and Polyfluoroalkyl Substances from Early Pregnancy to Delivery in the Atlanta African American Maternal–Child Cohort
Authors: Youran Tan, Stephanie M. Eick, Anne L. Dunlop, Dana Boyd Barr, Kaitlin R. Taibl, Kyle Steenland, Kurunthachalam Kannan, Morgan Robinson, Che-Jung Chang, Parinya Panuwet, Volha Yakimavets, Carmen J. Marsit, P. Barry Ryan, Donghai Liang
Journal: Environmental Health Perspectives (2024)

Longitudinal trends in per- and polyfluoroalkyl substances (PFAS) serum concentrations across pregnancy have not been thoroughly examined, despite evidence linking prenatal PFAS exposures with adverse birth outcomes.
Racial and Ethnic Disparities in Fentanyl and Polysubstance Overdose Deaths
Authors: David T. Zhu
Journal: JAMA Psychiatry (2024)

This cross-sectional study describes US overdose death patterns for fentanyl and fentanyl combined with opioids, heroin, cocaine, methamphetamine, or benzodiazepines by race and ethnicity from 2010 to 2022.